KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Share-based Compensation: 2013-2025

Historic Share-based Compensation for Ionis Pharmaceuticals (IONS) over the last 13 years, with Sep 2025 value amounting to $31.1 million.

  • Ionis Pharmaceuticals' Share-based Compensation fell 2.62% to $31.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $126.7 million, marking a year-over-year increase of 5.24%. This contributed to the annual value of $130.2 million for FY2024, which is 23.05% up from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Share-based Compensation is $31.1 million, which was up 4.90% from $29.7 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Share-based Compensation registered a high of $37.9 million during Q1 2021, and its lowest value of $22.3 million during Q4 2021.
  • Moreover, its 3-year median value for Share-based Compensation was $29.7 million (2025), whereas its average is $29.7 million.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Share-based Compensation crashed by 76.58% in 2021, and later soared by 37.26% in 2024.
  • Ionis Pharmaceuticals' Share-based Compensation (Quarterly) stood at $22.3 million in 2021, then climbed by 15.41% to $25.7 million in 2022, then rose by 2.52% to $26.3 million in 2023, then spiked by 37.26% to $36.1 million in 2024, then decreased by 2.62% to $31.1 million in 2025.
  • Its Share-based Compensation stands at $31.1 million for Q3 2025, versus $29.7 million for Q2 2025 and $29.7 million for Q1 2025.